Risk is just that, risk. Investing in opportunity is never easy but can return financial rewards. Understanding the risk is the key. Pick an investment that fits your needs. Finding that investment, and waiting to see if you are correct, is the key.

Rexahn Pharmaceuticals Inc., a clinical biopharmaceutical drug development company, works to develop drug products oriented toward a variety of conditions. The company is currently progressing through Phase IIa for an anti-depressant product.

Although the company has a variety of pharmaceutical products in development, its relationships around the world may be its largest asset. Universities to corporations have developed licensing arraignments with the company that will, in all likelihood, result in solid marketing and profitability as products become approved. These relationships may also result in opportunities as they relate to the company being purchased or leveraged by larger pharmaceutical companies. In the “big pharma” world this is a key trend

Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, recently announced that the company has received FDA approval to begin Phase II trials for Serdaxin™, for the treatment of major depressive disorders. Serdaxin is being developed as an orally administered, extended-release tablet for the treatment of depression and anxiety.

According to the World Health Organization, major depressive disorder is the leading cause of disability in the United States for ages 15 to 44. There are 154 million cases of depression reported worldwide each year, and this condition is nearly twice as prevalent in women as in men. Major depressive disorder is expected to become the second-leading cause of disability worldwide by the year 2020.

Serdaxin is a dual enhancer of serotonin and dopamine neurotransmitters. In preclinical studies, Serdaxin was shown to significantly improve an individual’s negative mood state and the loss of positive mood state,